Nexalin Technology, Inc. (NXL) NASDAQ

0.69

-0.0279(-3.88%)

Updated at December 24 01:00PM

Currency In USD

Nexalin Technology, Inc.

Address

1776 Yorktown

Houston, TX 77056

United States of America

Phone

713 660 1100

Sector

Healthcare

Industry

Medical - Devices

Employees

6

First IPO Date

September 16, 2022

Key Executives

NameTitlePayYear Born
Mark WhitePresident, CEO & Director538,0001962
David OwensChief Medical Officer, Member of Scientific Advisory Board & Director211,6881962
Carolyn SheltonExecutive VP of Clinical, Quality & Regulatory Affairs340,6121962
John Patrick ClaudeCo-Founder and Director of Engineering & Development0N/A
Justin Van FleetChief Financial Officer0N/A

Description

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.